In our current study we were able to demonstrate that CSF-NFL levels can clearly discriminate between slowly progressive neuroinflammatory (PPMS) and more rapid neurodegenerative (ALS) processes, but do not correlate with assessments of PPMS severity on a clinical disease scale. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.